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Abstract:  22 
Background: The use of high-risk HPV testing for surveillance and clinical applications is 23 
increasing globally and it is important that tests are evaluated to ensure they are fit for 24 
purpose. In this study, the performance of a new HPV genotyping test -The 25 
Papilloplex® HR-HPV test- was compared to two well established genotyping tests. 26 
Preliminary clinical performance was also ascertained for the detection of CIN2+ in a 27 
disease-enriched retrospective cohort. 28 
Methods: A panel of 500 cervical LBC samples with known clinical outcomes were tested 29 
by the Papilloplex® HR-HPV test. Analytical concordance was compared to two assays: 30 
Linear Array HPV Genotyping Test and Optiplex HPV Genotyping Test. Initial clinical 31 
performance for the detection for CIN2+ samples was performed and compared to that of two 32 
clinically validated HPV tests: the RealTime High Risk HPV test and Hybrid Capture 2 HPV 33 
Test. 34 
Results: High agreement for HR-HPV was observed between the Papilloplex and LA and 35 
Optiplex HPV tests (97% and 95% respectively); with Kappa for HPV 16 and 18 being 0.90 36 
and 0.81 compared to the LA and 0.70 and 0.82 compared to Optiplex. The sensitivity, 37 
specificity, PPV and NPV of Papilloplex for detection of CIN2+was 92%, 54%, 33% and 38 
96% respectively and was very similar to that observed with RealTime and HC2. 39 
Conclusion: Papilloplex HR-HPV test shows similar analytical performance to two HPV 40 
genotyping tests at the level of HR-HPV and type specific level. Preliminary data on clinical 41 
performance look encouraging although further longitudinal studies within screening 42 
populations are required to confirm this. 43 
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Introduction 44 
The use of high-risk HPV (HR-HPV) testing for the identification of women at risk of 45 
developing cervical cancer and for the management of women who have received treatment 46 
is increasing globally (1). Additionally, type specific HPV detection methods are valuable 47 
both for epidemiological studies and as a triage for primary HR-HPV infection (2). There are 48 
now a wide variety of commercially available HPV tests (3) which vary in terms of detection 49 
chemistry, complexity, type range, throughput and required equipment. While a component 50 
have been clinically validated for use in primary HPV screening through assessment 51 
according to internationally accepted criteria, or used extensively in longitudinal research and 52 
surveillance endeavours; peer reviewed evidence on the analytical and/or clinical 53 
performance of several tests is lacking.   54 
The Papilloplex® HR-HPV test (Genefirst, UK) is a commercially available HPV genotyping 55 
test that performs quantitative multiplex detection of 14 HR-HPV types, together with an 56 
endogenous human control target, in a single tube (4). Based on Multiplex Probe 57 
Amplification (MPA) technology, the assay utilises differing melting curve profiles to allow 58 
the differentiation of up to six targets per fluorescence channel within a real-time assay (4). 59 
The test is compatible with real-time polymerase chain reaction (PCR) equipment commonly 60 
used in clinical and research laboratories and so does not require a specific locked-down 61 
platforms.  62 
Here we present results from an evaluation of the Papilloplex HR-HPV assay where its 63 
performance is compared to two qualitative, broad spectrum, extended genotyping assays – 64 
the Linear Array (LA) HPV Genotyping Test (Roche Molecular Systems Inc., Alameda, CA, 65 
USA) and the Optiplex HPV Genotyping Kit (formerly Multiplex HPV Genotyping Kit, 66 
DiaMex, Heidelberg, Germany). Preliminary insight into clinical performance of the assay is 67 
also presented through its ability to detect CIN2+ in a disease-enriched sample compared to 68 
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two well established clinically validated HPV assays – Hybrid Capture 2 (HC2) HPV DNA 69 
Test (Qiagen Gaithersburg, Inc., MD, US) and the RealTime High Risk HPV test (Abbott 70 
Molecular, Des Plaines, IL, USA).  71 
 72 
Results 73 
Overall HR-HPV positivity in the cohort 74 
The study cohort consisted of 500 Thinprep® liquid based cytology (LBC) samples with 75 
known cytology and histology results (Table 1). The sample cohort of 500 was split into two 76 
extraction methods (250 extracted using manual QiaAmp DNA mini kit and 250 using 77 
automated Nuclisens EasyMag system). The concordance of Papilloplex at overall HR-HPV 78 
level and type specific level with LA and Optiplex showed no significant differences based 79 
on extraction chemistry (data not shown). The whole study cohort was therefore used for 80 
further analysis. Overall HR-HPV positivity for the genotyping tests and the clinically 81 
validated tests was similar: 58.4% for Papilloplex, 57.2% for LA, 56.4% for Optiplex, 56.2% 82 
for RealTime and 58.6% for HC2 (Table 2).  83 
Agreement between assays 84 
Agreement of overall HR-HPV positivity between Papilloplex and the two extended 85 
genotyping tests is shown in Table 3. High proportional agreement of 97% (95% CI- 95-98) 86 
was observed between Papilloplex and LA. Similarly, high proportional agreement of 95% 87 
(95% CI- 92-97) was observed between Papilloplex and Optiplex.  88 
Type specific concordance(s) between the Papilloplex and the two genotyping assays for HR-89 
HPV types 16,18,31,33,35,39,45,51,52,56,58,59,66 and 68 are shown in Table 4. Two by two 90 
tables for each type detected by Papilloplex (vs comparator test) are also presented in 91 
Supplementary Data (Table S1). When comparing the Papilloplex to the Optiplex test there 92 
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was at least “substantial” agreement (defined according to a kappa of 0.61 to 0.80) for all 93 
types except HPV 68 (0.548). The equivalent comparison of Papilloplex to LA showed at 94 
least substantial agreement (defined according to a kappa of 0.61 to 0.80) for all types except 95 
HPV 68 (0.573) and HPV 59 which at a Kappa of 0.614 was at the lower end of substantial 96 
agreement. Papilloplex detected fewer samples as positive for HPV 16 (N=98) compared to 97 
both LA (N=108) and Optiplex (N=146). Similarly for HPV 59, Papilloplex detected fewer 98 
samples as positive (N=20) compared to LA (N= 73) and Optiplex (N=28) which is reflected 99 
in the aforementioned Kappa value. Conversely, Papilloplex detected a higher number of 100 
HPV 31 (N=64) infections compared to LA (N=54) and Optiplex (N=40), and a higher 101 
number of HPV 33 (N=44) infections vs Optiplex (N=36). Papilloplex also detected a higher 102 
number of HPV 56 (N=32) infections compared to LA (N=22) but this was lower than those 103 
detected by Optiplex (N=43) (Table S1).  104 
Clinical performance for detection of Cervical intraepithelial neoplasia 2 or worse 105 
(CIN2+) 106 
Of the 500 samples in the panel 87 were associated with CIN2+. Sensitivity, specificity, 107 
positive predictive value (PPV) and negative predictive value (NPV) of the Papilloplex test 108 
for the detection of CIN2+ is summarised in Table 5, with values of 92%, 54%, 33% and 109 
96% respectively. These values were similar to the clinical performance of the HC2 and 110 
RealTime assays. 111 
Discussion 112 
Papilloplex HR- HPV test is a single tube test for the quantitative multiplex detection of 14 113 
HR-HPV types, together with an endogenous human control target. This study provides the 114 
first analytical assessment of the Papilloplex test compared to two commercially available 115 
HPV tests that offer extended genotyping capability: LA and Optiplex. Further, to gain 116 
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insight into the potential clinical performance of the assay a preliminary evaluation was 117 
undertaken to determine its ability to detect CIN2+ in a disease enriched population. 118 
Papilloplex showed high concordance to Optiplex and LA at the level of overall HR-HPV 119 
positivity with a proportional agreement of 95-97% and kappa of 0.90- 0.93. Type specific 120 
proportional agreement for all 14 HR-HPV types covered by Papilloplex was generally high 121 
although there were some type specific differences. Papilloplex showed moderate 122 
concordance to LA and Optiplex for HPV 16 and 59, detecting less infections and clearly, 123 
HPV 16 is an important type for both epidemiological and clinical applications. On the other 124 
hand, Papilloplex detected more HPV 31 infections compared to both comparator genotyping 125 
tests. Type specific differences between genotyping tests have been reported previously (5) 126 
and such differences are perhaps inevitable given the range of chemistries available. 127 
Nevertheless, these data reinforce the notion that for longitudinal surveillance exercises (in 128 
which monitoring prevalence and trends of HPV types is important), consistent use of the 129 
same test is important to avoid real changes being confounded by test chemistry. 130 
Furthermore, it is notable that the clinical performance of the Papilloplex assay was similar to 131 
that of two well established clinically validated tests indicating that type-specific differences 132 
(including for HPV 16) may not have significant implications for the detection of disease.  133 
This said, we accept that the clinical evaluation performed in this study was preliminary and 134 
that the sample used was enriched in nature and did not represent women from a cross section 135 
of the screening population. Consequently, the clinical performance observed in this study, 136 
will not be representative of performance in a screening population. Nevertheless, 137 
determining initial sensitivity (the key measure of performance for screening applications) of 138 
a novel HPV test for CIN2+ using a sample with high disease-prevalence has precedent (6, 7) 139 
and arguably showing performance relative to that of an assay in which clinical efficacy has 140 
been demonstrated also has value, even at an early stage. Furthermore, future clinical 141 
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validation of the test which builds on the present work but involves a longitudinal screening 142 
population and assessment according to internationally recognised validation criteria is  143 
planned (8, 9). 144 
The variety of HPV tests available with their different scope and capabilities provides users 145 
with options to choose the most appropriate test for a particular context and population. 146 
Papilloplex HPV is a single-tube assay that identifies 14 HR-HPV types. The ability to 147 
perform individual genotyping within a single closed-tube format reduces time and risk of 148 
contamination associated with more “open” genotyping systems. The assay is amenable to 149 
several DNA extraction chemistries, requires a low amount of input DNA and can be 150 
performed with existing real-time 96 well PCR platforms that are available in routine 151 
research and clinical laboratories. In terms of analytical performances we have shown that 152 
this assay compares favourably to existing more established extended genotyping assays. 153 
While initial data on clinical performance is encouraging, further longitudinal assessments 154 
will determine its potential use for screening and disease management.  155 
 156 
Material and methods 157 
Samples and approvals 158 
A total of 500 liquid based cytology samples (LBCs) were obtained from the Scottish HPV 159 
Archive (www.shine.mvm.ed.ac.uk/archive) which is a biobank designed to support HPV 160 
Research. The East of Scotland Research Ethics Service has given generic approval to the 161 
Scottish HPV Archive as a Research Tissue Bank (REC Ref 11/AL/0174) for HPV related 162 
research on archived samples. The Scottish HPV Archive is also registered with National 163 
Research Scotland (NRS) Lothian Bioresource. Samples were made available for the present 164 
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project through application to the archive steering committee (HPV Archive Application Ref 165 
0016). 166 
The samples used for the study included 473 samples collected from women attending their 167 
first routine smear at the age of 20 in Scotland, supplemented by 27 samples from women 168 
attending colposcopy clinics due to abnormal cytology (in order to enrich for CIN2+). 169 
Routine cytology classification was as per British Society for Clinical Cytology criteria (10). 170 
Cytology results were classed as negative (for any abnormality), low grade (borderline 171 
squamous changes, koilocytosis, and low grade dyskaryosis) and high grade (which includes 172 
moderate and severe dyskaryosis). Subsequent cytology and histology results were obtained 173 
through data linkage via Information Services Division, Scotland and samples were classified 174 
as 2x cytology negative (with 2 subsequent negative cytology results at least 1 year apart),   175 
≤CIN1 or CIN2+ (Table 1). Samples had originally been collected between 2010 and 2012 176 
and stored in the archive at -80oC.  177 
HPV DNA testing 178 
Samples were retrieved and aliquots prepared for HPV testing with Papilloplex HR-HPV test, 179 
HC2, Optiplex HPV genotyping test, LA and RealTime HR-HPV test. Papilloplex test was 180 
performed in Genefirst laboratories (Oxford, UK). All other tests were performed at the 181 
Scottish HPV Reference Laboratory and HPV Research Group (Edinburgh). All tests were 182 
performed according to manufacturer’s instructions although a brief description of assay 183 
characteristics is provided in Table 2 and a detailed description of the Papilloplex HR-HPV 184 
test is provided in the next section. The Optiplex genotyping test has been used for 185 
longitudinal immunisation surveillance in Scotland (11–13) and has been adjudicated as 186 
proficient for detection of HPV 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 187 
according to the last three consecutive WHO laboratory network (WHO LabNet) HPV DNA 188 
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proficiency schemes (when testing was performed in Edinburgh). LA is also associated with 189 
good performance on WHO LabNet proficiency panels as outlined in Eklund et al (2014) 190 
where it was the most frequently applied assay to the scheme (7). 191 
Papilloplex HPV test 192 
The Papilloplex HR-HPV test was performed on DNA extracted using two different methods. 193 
Half the samples were extracted using QiaAmp DNA mini kit (Qiagen,Germany) and half 194 
using automated Nuclisens EasyMag system (BioMérieux, France). The method of extraction 195 
was randomly allocated to samples.   196 
A total of 2µl of DNA was added to the PCR amplification reaction mix (18µl) containing 197 
buffer (dNTPs and Mg2+), master mix (Taq polymerase, UNG enzyme and dUTP) and 198 
working mix (primers and probes) to obtain a final volume of 20µl per PCR reaction. The 199 
PCR was performed on ABI 7500 Fast Real-Time PCR Systems (Applied Biosystems, 200 
Warrington, UK). The thermal profile was set to: Amplification stage 1 (50°C for 2 min, 201 
followed by 95°C for 3 min), amplification stage 2 (9 cycles of 95°C for 6 sec, followed by 202 
66°C for 45 sec), and amplification stage 3 (42 cycles of 95°C for 3 sec, followed by 60°C 203 
for 33 sec, and 63°C for 15 sec). Fluorescence measurements in the ROX, FAM, HEX (JOE), 204 
and CY5 channels were recorded during step 2 of amplification stage 3 (60°C for 33 sec). A 205 
pre-set dissociation stage (stage 4) was included following the final PCR cycle of 206 
amplification (stage 3). The post-amplification melting profile protocol comprised of 95°C 207 
for 15 sec, 25°C for 1 min, 75°C for 15 sec, and 60°C for 15 sec. The fluorescence emission 208 
data was continually collected during the temperature increase. The negative derivative of the 209 
emission reading, with respect to temperature, was plotted against the temperature to form 210 
melting curves (per fluorescent channel) generated during the dissociation stage of the 211 
reaction (from 25°C to 75°C).  212 
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For consistency between experiments, the following threshold values for Ct determination 213 
were set (ROX: 100,000; FAM: 100,000; HEX: 25,000 and CY5: 50,000). For each sample, 214 
the internal control (CY5 detection channel) and all fourteen HR-HPV types, corresponding 215 
to the ROX (HR-HPV types: 33, 35, 45, 51, 56, and 66), FAM (HR-HPV types: 16, 18, 31, 216 
52, and 59) and HEX channel (HR-HPV types: 39, 58, 68) were simultaneously evaluated. 217 
Samples were considered positive for HR-HPV DNA types if a Ct value was < 38 for cellular 218 
DNA and < 36 in any of the ROX, FAM and HEX fluorescent channels. A sample was 219 
considered invalid if the Ct value of cellular DNA was >38. The change in the characteristic 220 
melting profile(s) in the sample was compared to the negative control reference melting 221 
profile to identify the genotypes present. Samples were tested in batches of 96 samples 222 
(including controls) per reaction.   223 
Analysis  224 
HR-HPV concordance of the Papilloplex with comparator tests 225 
Type specific positivity for each HR-HPV type included in Papilloplex was compared to the 226 
Optiplex and LA. Concordance, proportional agreement with accompanying 95% confidence 227 
intervals (CI) have been presented along with kappa statistics and McNemar’s test. The 228 
Papilloplex was also compared to the above tests at the level of HR-HPV positivity (for the 229 
types covered by Papilloplex only). 230 
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Assessment of preliminary clinical performance  231 
Clinical performance of the Papilloplex test was measured as sensitivity, specificity, positive 232 
predictive value and negative predictive value for the detection of cervical CIN2+ with 95% 233 
CI’s around the percentages. The clinical performance of the HC2 and RealTime HPV test 234 
was also performed and presented alongside the Papilloplex results. Disease cases were 235 
defined as CIN2+ (n=87), whereas no disease was defined as histologically confirmed CIN1 236 
or less or a sample being associated with two consecutive negative cytology results at least 1 237 
year apart (n=349). Pathology data was incomplete to allow this categorisation for 64/500 238 
samples so clinical performance assessment was performed on 436 samples. 239 
 240 
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Results Tables  298 
Underlying Cytology  N (%) 
Negative  266 (53.2) 
Low grade dyskaryosis   156 (31.2) 
High grade dyskaryosis  66 (13.2) 
Unknown  12 (2.4%) 
Total 500 
Underlying Histology  
No histology performed (2 x Negative cytology) 263 (52.6) 
≤CIN1  86 (17.2) 
CIN2+ 87 (17.4) 
Histology information incomplete   64 (12.8) 
Table 1: Cervical pathology associated with study population. Note that clinical 299 
performance assessment was performed on 436 samples. Samples with incomplete 300 
histology was not included in this analysis.   301 
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Test 
Detection 
technology 
High-risk 
types 
identified by 
the test 
Low-risk 
types 
identified by 
the test 
High-risk 
positive (N, 
%) 
High- 
risk + 
Low-risk 
positive 
(N) 
Papilloplex HR- 
HPV test 
Real-time PCR 
with individual 
genotyping 
16, 18, 31, 33, 
35, 39, 45, 51, 
52, 56, 58, 59, 
66, 68 
 
292 (58.4%) 
 
RealTime HR-
HPV test 
Real-time PCR 
with partial 
genotyping 
16, 18, 31, 33, 
35, 39, 45, 51, 
52, 56, 58, 59, 
66, 68 
 
281 
(56.2%) 
 
Hybrid Capture 2 
(HC2) 
Target 
amplification 
followed by 
Sandwich capture 
assay 
16, 18, 31, 33, 
35, 39, 45, 51, 
52, 56, 58, 59, 
68 [not 66] 
 
293 
(58.6%) 
 
Linear Array 
HPV Genotyping 
test 
Target 
amplification 
followed by 
hybridisation 
16, 18, 31, 33, 
35, 39, 45, 51, 
52, 56, 58, 59, 
66, 68 
6, 11, 26, 40, 
42, 53, 54, 55, 
61, 62, 64, 67, 
69, 70, 71, 72, 
73, 81, 82, 83, 
84, IS39, 
CP6108 
286 
(57.2%) 
340 
(68.0%) 
Optiplex HPV 
genotyping test 
Target 
amplification 
followed by 
luminex detection 
16, 18, 31, 33, 
35, 39, 45, 51, 
52, 56, 58, 59, 
66, 68 
6, 11, 26, 42, 
43, 44, 53, 70, 
73, 82 
282 
(56.4%) 
321 
(64.2%) 
Table 2: Description of assays used in the study with the detection technology, types 302 
covered and prevalence of HPV in the study population.  303 
 304 
 305 
 306 
 307 
 308 
 309 
 310 
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Linear Array (LA) HPV Genotyping test 
  NEG POS 
Proportional 
agreement Kappa 
McNemars 
test: p-value 
Papilloplex HR- 
HPV test 
NEG 203 5 97% 
(95, 98) 0.934 0.210 POS 11 281 
Optiplex HPV genotyping test 
  NEG POS 
Proportional 
agreement Kappa 
McNemars 
test: p-value 
Papilloplex HR- 
HPV test 
NEG 200 8 95% 
(92, 97) 0.894 0.076 POS 18 274 
Table 3: Overall agreement between Papilloplex HR-HPV test and comparator tests. 311 
Concordance between the samples are indicated and proportional agreement with 95% 312 
CI (in brackets), kappa and McNemar’s test p-value are listed.  313 
  314 
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 HPV 
type 
Optiplex 
HPV test 
Linear array 
HPV test 
HPV 
type 
Optiplex 
HPV test 
Linear array 
HPV test 
Proportional 
agreement 
16 
89% 
(86, 91)  
97%  
(95, 98) 
51 
98%  
(96, 99) 
98% 
(97,99) 
Kappa 0.7 0.902 0.879 0.914 
McNemars test: 
p-value <0.001 0.021 1 0.727 
Proportional 
agreement 
18 
97%  
(95, 98) 
97% 
(95, 98) 
52 
96%  
(94, 97)  * 
Kappa 0.822 0.809 0.811 * 
McNemars test: 
p-value 0.286 0.077 0.664  * 
Proportional 
agreement 
31 
95%  
(93, 97) 
97%  
(95, 98) 
56 
97%  
(95, 98) 
98%  
(96, 99) 
Kappa 0.744 0.846 0.784 0.805 
McNemars test: 
p-value <0.001 0.021 0.007 0.002 
Proportional 
agreement 
33 
98%  
(97, 99) 
99%   
(97, 99) 
58 
98%  
(96, 99) 
98%  
(97, 99) 
Kappa 0.966 0.91 0.811 0.886 
McNemars test: 
p-value 0.008 0.453 0.146 0.727 
Proportional 
agreement 
35 
99%  
(98, 100) 
100%  
(99, 100) 
59 
98%  
(96, 99) 
95%  
(93, 97)  
Kappa 0.774 0.907 0.738 0.614 
McNemars test: 
p-value 0.125 1 0.039  <0.001 
Proportional 
agreement 
39 
97%  
(96, 99) 
98%   
(96, 99) 
66 
99%  (97, 
100) 
99%  
(97, 99) 
Kappa 0.851 0.937 0.915 0.908 
McNemars test: 
p-value 0.774 0.388 1 0.016 
Proportional 
agreement 
45 
99%  (96, 
99) 
99%  
(98, 100) 
68 
98%  
(97, 99) 
98%  
(96, 99) 
Kappa 0.867 0.924 0.548 0.573 
McNemars test: 
p-value 1 1 0.07 1 
Table 4: Type specific agreement of Papilloplex with Optiplex and Linear array (LA) 315 
HPV tests. Proportional agreement with 95% CI (in brackets), kappa and McNemar’s 316 
test p-value are indicated. *- Linear Array (LA) is unable to identify HPV-52 status in 317 
samples also positive for HPV33, HPV35, and/or HPV58. Results for HPV-52 is therefore 318 
not presented.   319 
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  Papilloplex HR- HPV test 
Hybrid 
Capture 2 
(HC2) 
RealTime HR-
HPV test 
Sensitivity 92% (84, 97) 91% (83, 96) 91% (83, 96) 
Specificity 54% (48, 59) 54% (48, 59) 56% (50, 61) 
PPV 33% (27, 39) 33% (27, 39) 34% (28, 40) 
NPV 96% (93, 99) 96% (92, 98) 96% (92, 98) 
Table 5: Clinical performance of HPV tests for detection of CIN2+. Sensitivity, 320 
Specificity, Positive predictive value (PPV) and Negative Predictive value (NPV) along 321 
with 95% CI (in brackets) are indicated.   322 
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